New methods for the surveillance of HIV drug resistance in the resource poor world

Current Opinion in Infectious Diseases

Volumn 21, Issue 6, 2008, Pages 653-658

  Buckton, Andrew J ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

HIV 1; Surveillance; Transmitted drug resistance

Indexed keywords

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL PRACTICE; DEVELOPING COUNTRY; DIAGNOSTIC PROCEDURE; DRIED BLOOD SPOT; GENOTYPE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; REVIEW; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; BLOOD; DESICCATION; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECIMEN HANDLING;

EID: 57049168664     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283186d1a     Document Type: Review

References (31)

1. World Health Organisation - briefing document. Towards universal access. WHO UNAIDS UNICEF; 2008. http://www.who.int/hiv/drugresistance/en/.
2. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
3. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004; 9:695-702.
4. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
5. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-1790.
6. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867-870.
7. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 2004; 30:1-10.
8. Plantier JC, Dachraoui R, Lemee V, et al. HIV-1 resistance genotyping on dried serum spots. AIDS 2005; 19:391-397.
9. Ziemniak C, George-Agwu A, Moss WJ, et al. A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods 2006; 136:238-247.
10. McNulty A, Jennings C, Bennett D, et al. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 2007; 45:517-521. This is an in-depth study reporting the development and implementation of a DBS genotyping assay. Analysis of proviral DNA contribution to DBS sequences was performed.
11. Masciotra S, Garrido C, Youngpairoj AS, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 2007; 21:2503-2511. This study reports highly concordant sequences between plasma and DBS, yet note the disparity in some resistance-associated mutation sites between the two specimen types.
12. Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
13. Bertagnolio S, Soto-Ramirez L, Pilon R, et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 2007; 12:107-113. An interesting study involving DBS stored in extreme field conditions.
14. Steegen K, Luchters S, Demecheleer E, et al. Feasibility of detecting HIV-1 drug resistance in DNA extracted from whole blood or dry blood spots. J Clin Microbiol 2007; 45:3342-3351. This study reports the comparison of HIV sequences obtained from DBS and liquid whole blood.
15. Youngpairoj AS, Masciotra S, Garrido C, et al. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 2008; 61:1217-1220.
16. Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol 2008; 41:283-287.
17. Garrido C, Zahonero N, Fernandes D, et al. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008; 61:694-698.
18. Buckton AJ, Bissett SL, Myers RE, et al. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother (in press).
19. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/HIV M ResNet drug resistance laboratory strategy. Antivir Ther 2008; 13 (Suppl 2): 49-57. A definitive guide to the WHO laboratory network and current best practice for the collection, storage, transport and testing of DBS.
20. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 (Suppl 2):1-13. An excellent review of the WHO strategy to monitor transmitted HIVDR in antiretroviral scale-up countries.
21. Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 2006; 19:607-614.
22. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 (Suppl 2):25-36.
23. Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008; 13 (Suppl 2):115-121.
24. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008; 13 (Suppl 2):95-100.
25. Abegaz WE, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 2008; 13 (Suppl 2):89-94.
26. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13 (Suppl 2):83-87.
27. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13 (Suppl 2):77-82.
28. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 (Suppl 2):101-107.
29. KewalRamani VN, Coffin JM. Virology. Weapons of mutational destruction. Science 2003; 301:923-925.
30. Mulder LC, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A 2008; 105:5501-5506.
31. Gifford PJ, Rhee SY, Eriksson N, et al. Sequence editing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS 2008; 22:717-725. An important study identifying numerous artefactual resistance-associated mutations likely to be found in some DBS-derived sequences.